Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 5/20 | 0.41 |
| ▸ | MGMT | P16455 | 3/20 | 0.41 |
| ▸ | CDK2 | P24941 | 4/20 | 0.40 |
| ▸ | CDK1 | P06493 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288236 | 0.85 | BRAF (0.48) | PDE4APDE4BPDE4CPDE4DPDPK1 | |
| SCHEMBL104931 | 0.84 | PDE4A (0.64) | CDC7DBF4PDE4APDE4BPDE4C | |
| SCHEMBL29557469 | 0.84 | PDE4A (0.64) | CDC7DBF4PDE4APDE4BPDE4C | |
| SCHEMBL16146202 | 0.80 | CDK1 (0.48) | CDC7DBF4PDE4APDE4BPDE4C | |
| SCHEMBL448638 | 0.80 | CDC7 (0.37) | CDC7DBF4PDE4APDE4BPDE4C | |
| SCHEMBL28460506 | 0.78 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DPDPK1 | |
| Adenine SCHEMBL7891002 | 0.77 | PI4KA (0.56) | CDC7DBF4PDE4APDE4BPDE4C | |
| Phosphoric Acid SCHEMBL27565804 | 0.77 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DPDPK1 | |
| SCHEMBL7833385 | 0.75 | MPO (0.45) | PDE4APDE4BPDE4CPDE4DPDPK1 | |
| SCHEMBL11583363 | 0.75 | PDPK1 (0.47) | PDE4APDE4BPDE4CPDE4DPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778239-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN'S SYNDROME | Can-Fite Biopharma Ltd. (IL) | 2007-05-02 | — | — | EP | claimed |
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | claimed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | claimed |
| WO-2006011130-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN’S SYNDROME | CAN-FITE BIOPHARMA LTD. (IL) | 2006-02-02 | — | — | WO | claimed |
| US-5688774-A | ANTIINFLAMMATORY AGENTS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-18 | — | — | US | claimed |
| EP-3906034-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | Can-Fite Biopharma Ltd. (IL) | 2021-11-10 | — | — | EP | disclosed |
| CN-113543790-A | Use of A for achieving a fat-reducing effect3Adenosine receptor ligands | 坎-菲特生物药物有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN-FITE BIOPHARMA LTD. (IL) | 2020-12-10 | — | — | US | disclosed |
| EP-3380104-B1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN FITE BIOPHARMA LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| CN-111447953-A | A3 adenosine receptor ligands for the management of cytokine release syndrome | 康菲生物制药有限公司 | 2020-07-24 | — | — | CN | disclosed |
| EP-3681538-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | Can-Fite Biopharma Ltd. (IL) | 2020-07-22 | — | — | EP | disclosed |
| WO-2020141535-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | CAN-FITE BIOPHARMA LTD. (IL) | 2020-07-09 | — | — | WO | disclosed |
| WO-2011107981-A1 | A3AR AGONISTS FOR THE TREATMENT OF UVEITIS | GOVERNMENT OF THE USA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2010134067-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR THE REDUCTION OF INTRAOCULAR PRESSURE | CAN-FITE BIOPHARMA LTD. (IL) | 2010-11-25 | — | — | WO | disclosed |
| US-20080300213-A1 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment | CAN-FITE BIOPHARMA LTD. (IL) | 2008-12-04 | — | — | US | disclosed |
| EP-1976494-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS | Can-Fite Biopharma Ltd. (IL) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007086044-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS | CAN-FITE BIOPHARMA LTD. (IL) | 2007-08-02 | — | — | WO | disclosed |
| EP-1778239-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN'S SYNDROME | Can-Fite Biopharma Ltd. (IL) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006011130-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN’S SYNDROME | CAN-FITE BIOPHARMA LTD. (IL) | 2006-02-02 | — | — | WO | disclosed |
| US-5688774-A | ANTIINFLAMMATORY AGENTS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | GPR119, ADORA2A, FABP4 | CDC7 3599/4885DBF4 2592/4885PDE4A 572/4885 |
| US-20080300213-A1 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment | ADORA3, ADORA2A, ADORA1 | CDC7 3571/4885DBF4 2045/4885PDE4A 349/4885 |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | ADORA2A, ADORA3, ADORA1 | CDC7 436/4885DBF4 3356/4885PDE4A 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.